Intrexon acquires Immunologix

Wednesday, November 2, 2011

Intrexon, a privately held synthetic biology company has acquired Immunologix. Immunologix specializes in transforming naïve B-cells to produce 100% human monoclonal antibodies that can target all antigen types including, but not limited to cancer cells, viruses, bacteria, toxins, plus those epitopes related to autoimmune diseases such as diabetes, lupus, rheumatoid arthritis and multiple sclerosis. Terms of the transaction were not disclosed.

[Read More]